|
|
|
Insider
Information: |
Orbimed Capital Gp Vii Llc |
Relationship: |
|
City: |
New York |
State: |
NY |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
9 |
|
Direct
Shares |
0 |
|
Indirect Shares
|
28,157,598 |
|
|
Direct
Value |
$0 |
|
|
Indirect Value
|
$508,882,267 |
|
|
Total
Shares |
28,157,598 |
|
|
Total
Value |
$508,882,267 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
13
|
4
|
Stock
price went up :
|
3
|
0
|
Stock
price went down : |
10
|
4
|
|
|
|
Gain/Loss Ratio : |
0.0
|
-4.0
|
Percentage
Gain/Loss : |
-38.0%
|
-137.5%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Synthorx, Inc. |
THOR |
10% Owner |
2018-12-11 |
0 |
2018-12-11 |
5,316,355 |
Premium* |
|
Arcutis Biotherapeutics, Inc. |
ARQT |
10% Owner |
2020-02-03 |
0 |
2022-06-24 |
415,142 |
Premium* |
|
Passage Bio, Inc. |
PASG |
10% Owner |
2020-02-28 |
0 |
2023-06-28 |
8,034,000 |
Premium* |
|
Enliven Therapeutics Ord Shs |
ELVN |
Director, 10% Owner |
2020-03-12 |
0 |
2021-07-16 |
4,199,068 |
Premium* |
|
Sierra Oncology Inc |
SRRA |
Director, 10% Owner |
2022-07-01 |
0 |
2022-07-01 |
0 |
Premium* |
|
Third Harmonic Bio, Inc. |
THRD |
Director, 10% Owner |
2022-09-19 |
0 |
2022-09-19 |
5,779,071 |
Premium* |
|
Galecto Inc. |
GLTO |
10% Owner |
2023-04-05 |
0 |
2023-08-15 |
1,510,375 |
Premium* |
|
Theseus Pharmaceuticals, Inc. |
THRX |
Director, 10% Owner |
2023-07-17 |
0 |
2023-07-17 |
650,600 |
Premium* |
|
Q32 Bio Inc |
QTTB |
|
|
0 |
2024-03-25 |
2,252,987 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
43 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 2
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
THOR |
Synthorx, Inc. |
10% Owner |
|
2018-12-11 |
4 |
B |
$11.00 |
$14,999,996 |
I/I |
1,363,636 |
1,363,636 |
1.5 |
- |
|
THOR |
Synthorx, Inc. |
10% Owner |
|
2018-12-11 |
4 |
A |
$0.00 |
$0 |
I/I |
3,952,719 |
5,316,355 |
0 |
- |
|
ARQT |
Arcutis Biotherapeutics, ... |
Director |
|
2020-02-03 |
4 |
B |
$17.00 |
$9,501,096 |
I/I |
558,888 |
176,500 |
2.25 |
- |
|
ARQT |
Arcutis Biotherapeutics, ... |
Director |
|
2020-02-04 |
4 |
A |
$0.00 |
$0 |
I/I |
4,114,962 |
606,286 |
0 |
- |
|
PASG |
Passage Bio, Inc. |
10% Owner |
|
2020-02-28 |
4 |
B |
$18.00 |
$6,719,400 |
I/I |
373,300 |
373,300 |
1.5 |
- |
|
PASG |
Passage Bio, Inc. |
10% Owner |
|
2020-03-03 |
4 |
A |
$0.00 |
$0 |
I/I |
5,574,023 |
5,947,323 |
0 |
- |
|
ELVN |
Enliven Therapeutics Ord ... |
Director |
|
2020-03-12 |
4 |
B |
$16.00 |
$15,000,000 |
I/I |
937,500 |
937,500 |
2.25 |
- |
|
ELVN |
Enliven Therapeutics Ord ... |
Director |
|
2020-03-16 |
4 |
A |
$0.00 |
$0 |
I/I |
1,594,902 |
2,532,402 |
0 |
- |
|
ARQT |
Arcutis Biotherapeutics, ... |
Director |
|
2020-10-02 |
4 |
B |
$25.00 |
$12,400,000 |
I/I |
496,000 |
902,286 |
2.25 |
% |
|
ELVN |
Enliven Therapeutics Ord ... |
Director |
|
2021-07-16 |
4/A |
B |
$6.00 |
$9,999,996 |
I/I |
1,666,666 |
4,199,068 |
2.25 |
- |
|
PASG |
Passage Bio, Inc. |
10% Owner |
|
2022-01-11 |
4 |
B |
$5.53 |
$45,346 |
I/I |
8,200 |
5,955,523 |
1.5 |
% |
|
PASG |
Passage Bio, Inc. |
10% Owner |
|
2022-01-12 |
4 |
B |
$5.65 |
$565,000 |
I/I |
100,000 |
6,055,523 |
1.5 |
% |
|
PASG |
Passage Bio, Inc. |
10% Owner |
|
2022-01-13 |
4 |
B |
$5.52 |
$230,736 |
I/I |
41,800 |
6,097,323 |
1.5 |
% |
|
PASG |
Passage Bio, Inc. |
10% Owner |
|
2022-01-14 |
4 |
B |
$5.60 |
$57,680 |
I/I |
10,300 |
6,107,623 |
1.5 |
% |
|
PASG |
Passage Bio, Inc. |
10% Owner |
|
2022-01-18 |
4 |
B |
$5.46 |
$626,262 |
I/I |
114,700 |
6,222,323 |
1.5 |
% |
|
PASG |
Passage Bio, Inc. |
10% Owner |
|
2022-01-19 |
4 |
B |
$5.11 |
$221,263 |
I/I |
43,300 |
6,265,623 |
1.5 |
% |
|
PASG |
Passage Bio, Inc. |
10% Owner |
|
2022-01-20 |
4 |
B |
$5.42 |
$2,000,522 |
I/I |
369,100 |
6,634,723 |
1.5 |
% |
|
PASG |
Passage Bio, Inc. |
10% Owner |
|
2022-01-20 |
4/A |
B |
$5.00 |
$254,000 |
I/I |
50,800 |
6,316,423 |
1.5 |
- |
|
ARQT |
Arcutis Biotherapeutics, ... |
10% Owner |
|
2022-04-06 |
4 |
S |
$20.69 |
$6,893,991 |
I/I |
(333,204) |
731,082 |
0 |
% |
|
ARQT |
Arcutis Biotherapeutics, ... |
10% Owner |
|
2022-04-07 |
4 |
S |
$20.66 |
$7,127,617 |
I/I |
(344,996) |
553,886 |
0 |
% |
|
ARQT |
Arcutis Biotherapeutics, ... |
10% Owner |
|
2022-04-08 |
4 |
S |
$20.71 |
$4,142,000 |
I/I |
(200,000) |
451,086 |
0 |
% |
|
PASG |
Passage Bio, Inc. |
10% Owner |
|
2022-05-03 |
4 |
B |
$1.93 |
$427,495 |
I/I |
221,500 |
6,537,923 |
1.5 |
% |
|
PASG |
Passage Bio, Inc. |
10% Owner |
|
2022-05-04 |
4 |
B |
$1.94 |
$588,790 |
I/I |
303,500 |
6,841,423 |
1.5 |
% |
|
ARQT |
Arcutis Biotherapeutics, ... |
10% Owner |
|
2022-06-24 |
4 |
S |
$21.31 |
$7,287,402 |
I/I |
(341,971) |
415,142 |
0 |
% |
|
SRRA |
Sierra Oncology Inc |
Director |
|
2022-07-01 |
4 |
D |
$55.00 |
$108,062,350 |
I/I |
(1,964,770) |
0 |
0 |
- |
|
43 Records found
|
|
Page 1 of 2 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|